摘要
PURPOSE: TP53 mutation, one of the most frequent mutations in early-stage lung adenocarcinoma (LUAD), triggers a series of alterations in the immune landscape, progression, and clinical outcome of early-stage LUAD. Our study was designed to unravel the effects of TP53 mutation on the immunophenotype of early-stage LUAD and formulate a TP53-associated immune prognostic model (IPM) that can estimate prognosis in early-stage LUAD patients. MATERIALS AND METHODS: Immune-associated differentially expressed genes (DEGs) between TP53 mutated (TP53(MUT) ) and TP53 wild-type (TP53(WT) ) early-stage LUAD were comprehensively analyzed. Univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) analysis identified the prognostic immune-associated DEGs. We constructed and validated an IPM based on the TCGA and a meta-GEO composed of GSE72094, GSE42127, and GSE31210, respectively. The CIBERSORT algorithm was analyzed for assessing the percentage of immune cell types. A nomogram model was established for clinical application. RESULTS: TP53 mutation occurred in approximately 50.00% of LUAD patients, stimulating a weakened immune response in early-stage LUAD. Sixty-seven immune-associated DEGs were determined between TP53(WT) and TP53(MUT) cohort. An IPM consisting of two prognostic immune-associated DEGs (risk score = 0.098 * ENTPD2 expression + 0.168 * MIF expression) was developed through 397 cases in the TCGA and further validated based on 623 patients in a meta-GEO. The IPM stratified patients into low or high risk of undesirable survival and was identified as an independent prognostic indicator in multivariate analysis (HR = 2.09, 95% CI: 1.43-3.06, p < 0.001). Increased expressions of PD-L1, CTLA-4, and TIGIT were revealed in the high-risk group. Prognostic nomogram incorporating the IPM and other clinicopathological parameters (TNM stage and age) achieved optimal predictive accuracy and clinical utility. CONCLUSION: The IPM based on TP53 status is a reliable and robust immune signature to identify early-stage LUAD patients with high risk of unfavorable survival.
学科与关键词
- Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy predictionZhang, Sainan; Li, Mengyue; Tan, Yilong; Zhang, Juxuan; Liu, Yixin; Jiang, Wenbin; Li, Xin; Qi, Haitao; Tang, Lefan; Ji, Ran; Zhao, Wenyuan; Gu, Yunyan*; Qi, Lishuang*Journal of Molecular Medicine, 2022, 100(12): 1755-1769.
- Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosisLiu, Mengfeng; Xiao, Qifan; Yu, Xiran; Zhao, Yujie; Qu, Changfa*Frontiers in Pharmacology, 2022, 13: 1081244.
- Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinomaSun, Hao; Liu, Si-Yang; Zhou, Jia-Ying; Xu, Jin-Tian; Zhang, Huang-Kai; Yan, Hong-Hong; Huan, Jiao-Jiao; Dai, Ping-Ping; Xu, Chong-Rui; Su, Jian; Guan, Yan-Fang; Yi, Xin; Yu, Rong-Shan; Zhong, Wen-Zhao; Wu, Yi-Long*EBioMedicine, 2020, 60: 102990.被引 89
